These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34797742)

  • 1. Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity.
    Zeng W; Zhang Q; Zhu Y; Ou R; Peng L; Wang B; Shen H; Liu Z; Lu L; Zhang P; Liu S
    Cancer Invest; 2022 Mar; 40(3):282-292. PubMed ID: 34797742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
    Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
    Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
    Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
    J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
    Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
    Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
    Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ
    Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Phely L; Hensen L; Faul C; Ruff CA; Schneider D; Bethge WA; Lengerke C
    JAMA Oncol; 2024 Jun; 10(6):821-824. PubMed ID: 38635232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.
    Becerril-Rico J; Delgado-Montes YA; Ortiz-Sánchez E
    Leuk Lymphoma; 2023; 64(11):1822-1831. PubMed ID: 37548560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.
    Velasco-Hernandez T; Zanetti SR; Roca-Ho H; Gutierrez-Aguera F; Petazzi P; Sánchez-Martínez D; Molina O; Baroni ML; Fuster JL; Ballerini P; Bueno C; Fernandez-Fuentes N; Engel P; Menendez P
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.
    Zanetti SR; Velasco-Hernandez T; Gutierrez-Agüera F; Díaz VM; Romecín PA; Roca-Ho H; Sánchez-Martínez D; Tirado N; Baroni ML; Petazzi P; Torres-Ruiz R; Molina O; Bataller A; Fuster JL; Ballerini P; Juan M; Jeremias I; Bueno C; Menéndez P
    Mol Ther; 2022 Feb; 30(2):550-563. PubMed ID: 34478871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.
    Jia H; Wang Z; Wang Y; Liu Y; Dai H; Tong C; Guo Y; Guo B; Ti D; Han X; Yang Q; Wu Z; Han W
    J Hematol Oncol; 2019 Jun; 12(1):57. PubMed ID: 31182121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
    Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
    Front Immunol; 2021; 12():728962. PubMed ID: 34691036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
    Liu S; Zhang X; Dai H; Cui W; Yin J; Li Z; Yang X; Yang C; Xue S; Qiu H; Miao M; Chen S; Jin Z; Fu C; Li C; Sun A; Han Y; Wang Y; Yu L; Wu D; Cui Q; Tang X
    Blood Cancer J; 2023 Apr; 13(1):60. PubMed ID: 37095120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model.
    Ba D; Li H; Liu R; Zhang P; Tang Y
    Apoptosis; 2023 Dec; 28(11-12):1534-1545. PubMed ID: 37243774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Versatile strategy for controlling the specificity and activity of engineered T cells.
    Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
    Ghorashian S; Lucchini G; Richardson R; Nguyen K; Terris C; Guvenel A; Oporto-Espuelas M; Yeung J; Pinner D; Chu J; Williams L; Ko KY; Walding C; Watts K; Inglott S; Thomas R; Connor C; Adams S; Gravett E; Gilmour K; Lal A; Kunaseelan S; Popova B; Lopes A; Ngai Y; Hackshaw A; Kokalaki E; Carulla MB; Mullanfiroze K; Lazareva A; Pavasovic V; Rao A; Bartram J; Vora A; Chiesa R; Silva J; Rao K; Bonney D; Wynn R; Pule M; Hough R; Amrolia PJ
    Blood; 2024 Jan; 143(2):118-123. PubMed ID: 37647647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.
    Li T; Cui Q; Liu S; Li Z; Cui W; Li M; Ma Y; Cao X; Zhu X; Kang L; Yu L; Wu D; Tang X
    Leuk Res; 2024 Oct; 145():107569. PubMed ID: 39208598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
    Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
    Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.